Neovii & Mundipharma entered into licensing agreement

| By | Drug Development, Pharmaceutical Distribution

Neovii pharmaceuticals AG of Rapperswil, Switzerland and Mundipharma have entered into an agreement giving Mundipharma the rights to develop and distribute its polyclonal antibody immunosuppressant Grafalon®, in China and Japan from end October.

Grafalon is indicated in solid organ transplant for prevention and treatment of acute rejection, graft-vs-host disease (GvHD) in stem cell transplant (SCT) and in the treatment of aplastic anemia. Grafalon is the recognised standard of care in leading transplant centers.

Under its license, Mundipharma intends to strengthen the distribution and support of Grafalon in these key markets to advance the clinical development for the prevention of chronic GvHD in SCT.

Grafalon is currently approved for prevention of rejection and the treatment of acute steroid resistant rejection in solid organ transplant in China.

Grafalon, has been used for over 30 years to treat patients, and is currently available in over 50 countries worldwide. Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology.

Neovii is an independent, dynamic, rapidly-growing and global biopharmaceutical company that has been dedicated for over three decades to improving the outcomes in transplantation medicine and the treatment options for hemato-oncological as well as immune disorders. Neovii Pharmaceuticals AG’s global headquarters is located in Rapperswil, Switzerland and has a branch office in Massachusetts, USA. Its biotechnology manufacturing facility is in Graefelfing, Germany. Neovii’s products are available in over 50 countries worldwide.

Mundipharma is a network of independent associated companies which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore.

SOURCE: prnewswire
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.